Publication at Faculty of Medicine in Hradec Králové |
2018
Abstract
Vedolizumab (VDZ), a humanized monoclonal antibody, is approved for use in ulcerative colitis and Crohn's disease (IBD).Vedolizumabinhibits leukocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. Clinicaleffectiveness of vedolizumab was evident in both the CD and mainly in UC populations.
These findings are consistent withobservations from clinical trials, and from real word experience too. The improved safety profile, novel mechanism of action andclinical need for new therapies has led to the rapid adoption of vedolizumab use in clinical practice.
